Tarus Therapeutics

Tarus Therapeutics is a biotechnology company focused on nucleotide metabolism in cancer. The company’s lead programs target the immunosuppressive adenosine pathway in the tumor microenvironment (TME) for the treatment of resistant cancers. Adenosine is recognized as a key metabolic checkpoint, and high levels of extracellular adenosine have been evidenced to mediate profound tumor resistance. Selective inhibition of adenosine receptors A2AR and A2BR thus represents a promising approach for cancer immunotherapy. Tarus is developing one of the most comprehensive portfolio of adenosine receptor antagonists in the industry with highly potent and selective antagonists for A2A and A2B receptors, including a novel “dual” antagonist.

  • Adenosine
  • Pipeline
  • Non-Oncology Indications

Adenosine is a key suppressor of immune cells in the tumor microenvironment (TME).

Extracellular adenosine elicits a major immunosuppressive signal through adenosine A2A and A2B receptors, thwarting anti-tumor immunity.

Adenosine’s role in immune suppression is corroborated by observations that the TME has significantly elevated concentrations (100-500 fold) of extracellular adenosine.


Our robust clinical pipeline includes small molecule, biologic and cellular therapies for the treatment of cancer. The TARUS team continues to fuel the rapid expansion of this clinical pipeline.

Taken together, our clinical pipeline balances a range of therapeutic approaches for the treatment of cancer to enable us to improve the lives of cancer patients.

Non-oncology indications

Tarus Therapeutics is focused on developing its platform of adenosine antagonists for a range of oncology indications. Tarus also has extensive data for various non-oncology indications including Parkinson’s, Sickle cell Disease, Ulcerative Colitis and Lung Fibrosis.

This data includes support for target engagement, PK/PD, safety and other drug properties.